Literature DB >> 32561286

Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling pathway.

Tingting Yang1, Yi Zhou1, Haiyan Wang1, Shangxiu Chen1, Mengli Shen2, Yinlu Hu1, Tao Wang3, Junjie Liu4, Zhenzhou Jiang5, ZhongJian Wang1, Xia Zhu1, Sitong Qian1, Xiaoxing Yin1, Qian Lu6.   

Abstract

As two most common progressive diseases of aging, type 2 diabetes mellitus (T2DM) and benign prostatic hyperplasia (BPH) were all characterized by endocrine and metabolic disorders. Here, our clinical study showed that there were significant differences in fasting blood glucose (FBG), fasting insulin (FINS), insulin resistance index (HOMA-IR) and prostate volume (PV) between simple BPH patients and BPH complicated with T2DM patients. Further analysis showed that HOMA-IR was positively correlated with PV in BPH complicated with T2DM patients. The in vitro experiment results showed that high glucose (HG) promoted EMT process in a glucose-dependent manner in human prostate hyperplasia cells (BPH-1) and prostate cancer cells (PC-3), and this pathological process was exacerbated by co-culture with insulin. Mechanistically, insulin-induced exacerbation of EMT was depended on the activation of MEK/ERK signaling pathway, and we suggested that insulin and its analogs should be used very carefully for the clinical antihyperglycemic treatment of BPH complicated with T2DM patients.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Benign prostatic hyperplasia; Epithelial-mesenchymal transition; High glucose; Insulin; MEK/ERK signaling Pathway; Type 2 diabetes mellitus

Year:  2020        PMID: 32561286     DOI: 10.1016/j.yexcr.2020.112145

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  4 in total

1.  Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity.

Authors:  Xiao Yang; Jiancheng Lv; Zijian Zhou; Dexiang Feng; Rui Zhou; Baorui Yuan; Qikai Wu; Hao Yu; Jie Han; Qiang Cao; Min Gu; Pengchao Li; Haiwei Yang; Qiang Lu
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

2.  Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma.

Authors:  Zhaoxin Guo; Xiaolin Hu; Renguang Lv; Yongzhen Zhang; Liwei Meng; Zhaoxu Liu; Lei Yan
Journal:  Dis Markers       Date:  2022-08-17       Impact factor: 3.464

3.  Identification of key genes in benign prostatic hyperplasia using bioinformatics analysis.

Authors:  Peng Xiang; Dan Liu; Di Guan; Zhen Du; Yongxiu Hao; Wei Yan; Mingdong Wang; Hao Ping
Journal:  World J Urol       Date:  2021-02-09       Impact factor: 4.226

4.  Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes.

Authors:  Andras Franko; Lucia Berti; Jörg Hennenlotter; Steffen Rausch; Marcus O Scharpf; Martin Hrabĕ de Angelis; Arnulf Stenzl; Andreas L Birkenfeld; Andreas Peter; Stefan Z Lutz; Hans-Ulrich Häring; Martin Heni
Journal:  J Pers Med       Date:  2020-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.